Immutep (ASX:IMM) said its phase 2b trial evaluating eftilagimod alpha in combination with Keytruda for patients with head and neck squamous cell cancer showed "strong" overall survival, progression-free survival, and durability, according to a Thursday filing with the Australian bourse.
The 12-month overall survival rate was 67%, well above historical controls, while the interim median duration of response was 9.3 months, the filing said. The median overall survival has not yet been reached.
The Tacti-003 study also found the combination therapy continues to be well-tolerated, with no new safety concerns identified, the filing said.
The biotechnology company's shares rose nearly 3% in afternoon trade Thursday.
Price (AUD): $0.37, Change: $+0.01, Percent Change: +2.82%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。